Abstract

Background: The purpose of this study is to outline the probable causes of severe postpartum hemorrhage (sPPH), summarize its risk factors, and present strategies for its prevention and treatment. Methods: This is a retrospective analysis of the medical records of 1824 patients that showed postpartum hemorrhage (PPH) during natural delivery and were admitted to the Fourth Hospital of Shijiazhuang between 1 January, 2014 and 31 December, 2018. The pairing method was used in this study. We collected and analyzed the clinical data after dividing the patients into two groups, a study group (showing sPPH) and a control group (showing non-severe PPH), with each having 912 patients. Risk prevention strategies are also discussed. Results: In the study group, the conditions such as previous history of cesarean section, placental diseases (marginal placenta previa, placenta accreta, central placenta previa and low-lying placenta), IVF-ET pregnancy, antepartum hemorrhage, and prepartum hemoglobin (g/L) were prevalent but rarely reported in the control group. The multivariate logistic regression results showed that BMI before pregnancy, past history of postpartum hemorrhage, prepartum APTT, prepartum fibrinogen (FIB) (g/L), pre-transfusion hemoglobin (g/L), pre-transfusion platelet count (×109), pre-transfusion coagulation function prothrombin time (PT), marginal placenta previa, placenta accreta, central placenta previa, IVF-ET pregnancy and antepartum hemorrhage were all independent risk factors for sPPH. Conclusions: Probable causes of sPPH related and risk factors in order to present prevention and treatment strategies in a retrospective analysis of 1824 patients that showed PPH were outlined. Since occurrence of sPPH has been related to these various factors, constructing a risk prevention strategy against these independent factors can effectively reduce the rate of maternal mortality.

1. Introduction

According to the World Health Statistics, as of 2017, approximately 295,000 maternal deaths occur worldwide every year, and the global maternal mortality rate is as high as 2.11/100,000 [1]. The maternal mortality rate in high-income countries is 11/100,000.

Postpartum hemorrhage (PPH) is the leading cause of maternal death in the world. In addition, severe postpartum hemorrhage (sPPH) is defined as blood loss 1000 mL within 24 hours after delivery in the ninth edition of Chinese textbook of Obstetrics and Gynecology, which is considered a life-threatening condition. Therefore, the prediction of sPHH occurrence during pregnancy is essential to ensure the safety of pregnant women. In this study, we have analyzed the high-risk factors that contribute to sPPH.

2. Patients and Methods
2.1 Patients

The medical records of PPH patients from 1 January, 2014 to 31 December, 2018 were collected from the Fourth Hospital of Shijiazhuang, and the pairing method was used for their analysis. These patients underwent the same delivery procedure and were divided into a study group and a control group. Both the study group and the control group comprised 912 cases of pregnant patients with a blood loss of either 1000 mL or <1000 mL respectively, within 24 h after the delivery.

Inclusion criteria: the discharge date was between 1 January, 2014 and 31 December, 2018; the PPH volumes in the research group were 1000 mL, and the in the control group were <1000 mL; the complete medical records were available.

2.2 Methods

A data questionnaire was designed, which included age, height, weight, education, residence, parity, number of fetuses, history of cesarean delivery, history of miscarriage, time of delivery initiation, mode of labor initiation, in vitro fertilization-embryo transfer (IVF-ET) pregnancy, antepartum hemorrhage, preeclampsia, pregnancy complications and any known coagulation disorders. The retrospective research method was used to statistically analyze the data of pregnant patients who met the inclusion criteria and to summarize the relevant risk factors.

Based on the amount of blood loss during PPH, the patients were divided into a study group and a control group. The data from both groups were retrospectively analyzed; the risk factors of sPPH were evaluated by one-way analysis of variance and multivariate logistic regression. A logistic regression model was constructed to predict the risk factors for sPPH.

2.3 Statistical Analysis

The data were statistically analyzed using the R-4.3.2 software (https://cran.r-project.org/). Measurement data were analyzed by t-test or rank sum test, and calculated values were expressed as mean ± standard deviation (SD) or median [P25, P75]; enumeration data were expressed by χ2 test and expressed in frequency (%). Univariate and multivariate logistic regression tests were used to analyze the risk factors of sPPH during delivery. p < 0.05 was considered statistically significant.

3. Results

The education level, body mass index (BMI) before pregnancy, BMI before delivery, single pregnancy, multiple pregnancy, previous history of postpartum hemorrhage, previous history of cesarean section, birth weight, hemoglobin before delivery (g/L), platelet count before delivery (×109), prepartum coagulation function prothrombin time (PT), prepartum activated partial thromboplastin time (APTT), prepartum fibrinogen (FIB) (g/L), pre-transfusion hemoglobin (g/L), pre-transfusion platelet (×109), pre-transfusion coagulation function PT, pre-transfusion APTT, pre-transfusion TT, pretransfusion FIB (g/L), marginal placenta previa, placenta accreta, central placenta previa, low lying placenta, IVF-ET pregnancy and antepartum hemorrhage were risk factors for severe PPH according to t-test or rank sum test (Table 1).

Table 1.Risk factors of sPPH.
PPH (%) sPPH (%) p value
Primipara/multipara 0.606
Primipara 433 (47.5) 422 (46.3)
Multipara 479 (52.5) 490 (53.7)
Number of pregnancies 0.909
One 716 (78.5) 714 (78.3)
More than one 196 (21.5) 198 (21.7)
Number of deliveries 0.911
One 707 (77.5) 709 (77.7)
More than one 205 (22.5) 203 (22.3)
Residence 0.491
City 603 (66.1) 589 (64.6)
Village 309 (33.9) 323 (35.4)
Education 0.012
Below undergraduate level 471 (51.6) 502 (55.0)
Bachelor degree 175 (19.2) 126 (13.8)
Above undergraduate level 40 (4.4) 18 (2.0)
Unknown 226 (24.8) 266 (29.2)
Age (years) 30.48 ± 4.54 30.61 ± 4.84 0.554
BMI before pregnancy (kg/m2) 24.12 ± 3.51 22.01 ± 3.93 <0.001
BMI before delivery (kg/m2) 30.11 ± 4.01 28.17 ± 4.08 <0.001
Weight gain during pregnancy (kg) 15.0 (12.0, 19.0) 16.0 (12.0, 20.0) 0.009
Single pregnancy/multiple pregnancy <0.001
Single pregnancy 912 (100.0) 842 (92.3)
Multiple pregnancy 0 (0.0) 70 (7.7)
Previous history of postpartum hemorrhage <0.001
None 909 (99.7) 892 (97.8)
Yes 3 (0.3) 20 (2.2)
Previous history of cesarean section 0.026
None 750 (82.2) 712 (78.1)
Yes 162 (17.8) 200 (21.9)
Previous history of abortion and curettage 0.324
None 427 (46.8) 406 (44.5)
Yes 485 (53.2) 506 (55.5)
Birth weight (kg) 3.33 ± 0.05 3.71 ± 0.07 <0.001
Mode of labor initiation 0.910
Natural start 266 (29.2) 261 (28.6)
Induction of labor 243 (26.6) 251 (27.5)
Not started 403 (44.2) 400 (43.9)
Hemoglobin before delivery 109.73 ± 16.68 114.28 ± 14.11 <0.001
Hematocrit before delivery (%) 32.41 ± 5.82 34.74 ± 3.32 <0.001
Previous history of other uterine surgery 0.325
None 850 (93.2) 839 (92.0)
Yes 62 (6.8) 73 (8.0)
Platelet count before delivery (×109) 181.98 ± 77.86 213.79 ± 59.86 <0.001
Prepartum coagulation function PT 11.27 ± 2.51 10.61 ± 1.24 <0.001
Prepartum TT 13.3 (12.7, 14.0) 13.6 (13.0, 14.0) 0.321
Prepartum APTT 28.87 ± 5.66 28.34 ± 3.37 <0.001
Prepartum FIB (g/L) 4.0 (3.7, 4.4) 3.8 (3.4, 4.3) 0.041
Pre-transfusion hemoglobin (g/L) 108.81 ± 19.82 89.42 ± 21.57 <0.001
Pre-transfusion hematocrit (%) 25.84 ± 7.80 26.32 ± 6.59 0.155
Pre-transfusion platelet (×109) 120.3 (102.8, 135.5) 96.3 (70.6, 121.0) <0.010
Pre-transfusion coagulation function PT (s) 10.3 (9.2, 10.6) 12.4 (12.1, 13.0) <0.010
Pre-transfusion APTT 30.51 ± 10.89 34.44 ± 14.65 0.022
Pre-transfusion TT 6.1 (5.3, 7.2) 15.1 (14.1, 15.6) <0.010
Pretransfusion FIB (g/L) 12.8 (12.2, 13.3) 4.2 (3.1, 11.1) <0.010
Marginal placenta previa <0.001
None 908 (99.6) 882 (96.7)
Yes 4 (0.4) 30 (3.3)
Placenta accreta <0.001
None 911 (99.9) 797 (87.4)
Yes 1 (0.1) 115 (12.6)
Central placenta previa <0.001
None 911 (99.9) 881 (96.6)
Yes 1 (0.1) 31 (3.4)
Low lying placenta 0.012
None 910 (99.8) 901 (98.8)
Yes 2 (0.2) 11 (1.2)
IVF-ET pregnancy 0.004
None 908 (99.6) 895 (98.1)
Yes 4 (0.4) 17 (1.9)
Antepartum hemorrhage <0.001
None 912 (100.0) 898 (98.5)
Yes 0 (0.0) 14 (1.5)
Preeclampsia 0.123
None 855 (93.8) 838 (91.9)
Yes 57 (6.3) 74 (8.1)

PPH, postpartum hemorrhage (non-serve sPPH, control); sPPH, severe postpartum hemorrhage; BMI, body mass index; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; FIB, fibrinogen; IVF-ET, in vitro fertilization-embryo transfer. 912 patients in each group.

The BMI before pregnancy, past history of postpartum hemorrhage, birth weight prepartum APTT, prepartum FIB (g/L), pre-transfusion hemoglobin (g/L), pre-transfusion platelet (×109), pre-transfusion coagulation function prothrombin time (PT), marginal placenta previa, placenta accreta, central placenta previa, IVF-ET pregnancy and antepartum hemorrhage were risk factors for severe PPH according to multivariate analysis (Table 2).

Table 2.Multivariate analysis of sPPH.
Regression coefficients OR (95% CI) p value
Education 0.022 1.022 (0.978–1.068) 0.331
BMI before pregnancy (kg/m2) –0.257 0.774 (0.606–0.987) 0.039
BMI before delivery (kg/m2) –0.001 0.999 (0.768–1.300) 0.709
Single pregnancy/multiple pregnancy –0.332 0.718 (0.328–1.569) 0.406
Past history of postpartum hemorrhage 2.071 7.933 (1.144–55.022) 0.036
Previous history of cesarean section 0.480 1.616 (0.940–2.778) 0.082
Birth weight (kg) 1.492 9.524 (1.220–3.570) 0.046
Hemoglobin before delivery (g/L) –0.012 0.988 (0.928–1.052) 0.709
Hematocrit before delivery (%) 0.150 1.162 (0.890–1.517) 0.271
Platelet count before delivery (×109) 0.005 1.005 (0.995–1.015) 0.325
Prepartum coagulation function PT –0.150 0.860 (0.621–1.193) 0.367
Prepartum APTT 0.110 1.116 (1.006–1.238) 0.038
Prepartum FIB (g/L) 2.198 9.003 (2.129–38.066) 0.003
Pre-transfusion hemoglobin (g/L) –0.480 0.953 (0.918–0.991) 0.015
Pre-transfusion platelet (×109) 0.250 1.026 (1.009–1.043) 0.003
Pre-transfusion coagulation function PT 0.392 1.480 (1.079–2.030) 0.015
Pre-transfusion APTT –0.018 0.982 (0.871–1.108) 0.772
Pre-transfusion TT 0.600 1.062 (0.852–1.324) 0.591
Pretransfusion FIB (g/L) 0.190 1.019 (0.815–1.275) 0.867
Marginal placenta previa 2.571 13.082 (2.146–79.744) 0.005
Placenta accreta 1.931 6.899 (0.728–65.405) 0.092
Central placenta previa 3.297 27.035 (6.547–111.642) 0.004
Low lying placenta 2.131 8.419 (0.839–84.447) 0.070
IVF-ET pregnancy 3.141 23.125 (2.491–214.656) 0.006
Antepartum hemorrhage 2.874 9.268 (3.176–79.628) 0.003

OR, odds ratio; 95% CI, 95% confidence interval. The significant variables in Table 1 were included in the analysis.

4. Discussion

Hence, many clinical research studies have focused on assessing obstetric complications. In this study, we found that most deaths occurred within 24 h after the delivery of the baby; a compensated state can rapidly transition to decompensated state and is easily overlooked. PPH can be reduced through the identification of high-risk patients, early surgical preparations, and continued vigilance. PPH can be caused by uterine atony, birth canal injury, placental factors, and coagulation dysfunction. These four major causes are interconnected and mutually causal [2]. About 70%–80% of PPH is due to abnormal uterine tension (uterine atony). It is considered the primary cause of postpartum hemorrhage [3]. In this study, we have demonstrated that there are statistically significant differences if certain factors such as previous history of cesarean section, marginal placenta previa, placenta accreta, central placenta previa, and low-lying placenta are compared between the study and the control groups. Also, marginal placenta previa, placenta accreta and central placenta previa are the separate risk factors for sPPH.

Li et al. [4] found that placenta previa could increase the incidence of PPH by 6 to 20 times. They also reported that the incidence of PPH in patients with placenta previa can vary from 22.06% to 42.09%. The incidence of PPH in patients with placenta previa is as high as 38.20% [5], and the incidence of PPH in central placenta previa is 58% [6]. We also confirmed that placental disease is an independent risk factor that contributes significantly (foremost factor) to sPPH. Miscarriages, intrauterine operations and application of IVF-ET are also contributing factors to placental diseases. The larger the area of the internal cervical os covered by the placenta, the higher the risk of PPH. Central placenta previa is more likely to cause sPPH than marginal placenta previa or low lying placenta. The main reason for the formation of placenta previa is primary decidual dysplasia or an endometrial defect, mostly caused by trauma, resulting in a lack of the decidua basalis and adequate blood supply. The placenta covers the lower segment of the uterus and the internal os of the cervix [7]. The placenta has abundant blood vessels, but the muscle layer at this lower segment is weak, and the placenta has abundant blood vessels with resulting weak uterine contractility. When the placenta is stripped during labor, the blood sinuses on the stripped surface are open, which then induces PPH. In addition, the wound closure is delayed, and the amniotic fluid potentially enters the maternal blood vessels inducing acute disseminated intravascular coagulation, thus, affecting coagulation function and leading to excessive bleeding. Li et al. [4] reported that placenta accreta increases the risk of PPH by 7 to 11 times. Placenta accreta is the condition when the villi invade the myometrium and prevents the placenta from separating from the uterine wall. Insufficient uterine contractions or prolonged opening of blood sinuses during delivery may lead to difficulty in blood coagulation on the adhesion surface, which can also contribute to PPH. Therefore, preventing placental disease during pregnancy, especially central placenta previa with placenta accreta, and improving the existing standard treatment for placenta accreta, specifically the surgical procedures, are keys to preventing sPPH.

DiMarco et al. [8] found that pregnant patients with a medical history of multiple abortions have a significantly higher incidence of postpartum complications. The main reason could be that the uterine contractility is significantly reduced after multiple abortions, and the placenta is more likely to form abnormally in subsequent pregnancy, increasing the risk of PPH. We report that a history of multiple miscarriages is related to sPPH [9]. Therefore, medical personnel should educate young women about the proper use of contraception and its advantages. High-risk factors that cause placental disease should be considered in order to develop preventive measures and to avoid pregnancy complications, especially in women with short stature or those with insufficient weight gain during pregnancy.

Cui et al. [10] confirmed that the level of fibrinogen positively correlates with gestational age. A high level of fibrinogen can decrease the PT and partially activated PT which may reduce the occurrence of PPH. Fibrinogen varies from 2.4 to 4 g/L in adults, but it ranges from 3.4 to 5.4 g/L in the third trimester of pregnancy. The amount of maternal plasma fibrinogen has important predictive significance for PPH. van Dijk et al. [11] has found that the platelet count before childbirth is also closely related to the occurrence of PPH with the risk of PPH being high when the platelet count is low. Our results corroborate this finding.

This study demonstrates that a previous history of PPH, IVF-ET pregnancy, prepartum APTT, prepartum FIB (g/L), pre-transfusion hemoglobin (g/L), pre-transfusion platelet (×109) and pre-transfusion coagulation function prothrombin time (PT) are independent risk factors for sPPH. A higher level of hemoglobin (g/L) and prepartum hematocrit (%) can reduce the risk of sPPH. Therefore, detection and timely treatment of anemia during pregnancy are important for the prevention of sPPH [12]. Screening and therapeutical management of coagulation disorders during pregnancy and immediately before childbirth should also be considered a preventive measure for sPPH [13]. Diseases that may cause coagulation disorders include obstetric antiphospholipid syndrome (OAPS), thrombophilia, systemic lupus erythematosus, Sjögren’s syndrome, lupus nephritis, and other autoimmune diseases. Patients exhibiting any of these entities are prone to sPPH. One of the prevention and treatment plans that can effectively control the rate of bleeding is to immediately start the blood transfusion process. It diminishes the probability of the rapid onset of sPPH.

5. Conclusions

The system, infrastructure, technology, and trained personnel are all present. It is critical to strictly abide by the core system to follow the diagnosis and treatment specifications and provide team simulation training and individual skill training to healthcare professionals. We summarize it as the “5 early” principles, indicating early prediction, early warning, early prevention, early planning and early treatment are important to manage PPH. The etiology for sPPH is diverse and complicated in many pregnant patients during childbirth. For women of childbearing age, especially those exhibiting high-risk factors, evaluating the risk of PPH before pregnancy, providing special health care during pregnancy and delivery, taking preventive measures in advance, and managing the bleeding by medications are the keys to reducing sPPH [14]. A comprehensive treatment strategy for sPPH can effectively reduce the morbidity and mortality for pregnant patients.

Availability of Data and Materials

The availability of these data is restricted due to privacy or ethical considerations. The data supporting the findings of this study can be obtained upon request from the corresponding author.

Author Contributions

GZ contributed to the design of the study and conception of content. YZhang and JZ contributed to the study concepts, study design and data analysis. KG contributed to the literature research, data acquisition and manuscript preparation. YG contributed to the data curation and analysis. YZhu contributed to the literature research and manuscript preparation. All authors have read and approved the final version of the manuscript. All authors contributed to editorial changes in the manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

The study was approved by the institutional review board of Shijiazhuang Fourth Hospital (approval number 20190067) in accordance with the October 2013 edition of the Declaration of Helsink. All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all individual patients included in the study.

Acknowledgment

We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.

Funding

This work was supported by Hebei Provincial Department of Science and Technology Special Project for People’s Livelihood Science and Technology (NO.202030701180541). This research was supported by the Key Research and Development Program of Hebei Province (No.20377779D).

Conflict of Interest

The authors declare no conflict of interest.

References

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.